Abciximab in the treatment of acute coronary syndromes by angioplasty and stent;Abciximab dans le traitement des syndromes coronariens aigus par angioplastie et stent

Therapie

Volumn 53, Issue 4, 1998, Pages 341-347

  Pinton, P ^a  

^a U Therapeutique Cardio vasculaire ^*  (France)

Author keywords

Abciximab; Coronary angioplasty; Glycoprotein IIb IIIa; Platelet aggregation inhibitors; Stent

Indexed keywords

ABCIXIMAB; MONOCLONAL ANTIBODY;

ARTICLE; CORONARY ARTERY DILATATION; DRUG EFFICACY; HEART MUSCLE ISCHEMIA; HEART MUSCLE REVASCULARIZATION; PRIORITY JOURNAL; STENT;

ACUTE DISEASE; ANGIOPLASTY; ANTIBODIES, MONOCLONAL; ANTICOAGULANTS; COMBINED MODALITY THERAPY; CONTROLLED CLINICAL TRIALS; CORONARY DISEASE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; STENTS;

EID: 0032445131     PISSN: 00405957     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Balcon R, Beyar R, de Scheerder I et al. Recommendations on stent manufacture, implantation and utilization. Working group report. Eur Heart J 1997; 18: 1536-1547.
2. Barragan P, Sainsous J Silvestri M et al. Ticlopidine and subcutaneous heparin as an alternative regimen following coronary stenting. Cathet Cardiovasc Diagn 1994; 32: 133-138.
3. Zemour G, Morice MC, Benveniste E et al. Implantation de prothèses endocoronaires sans vitamine K. Résultats à un mois. Arch Mal Cœur 1996; 89: 291-297.
4. Lablanche JM, Mc Fadden EP, Bonnet JL et al. Combined antiplatelet therapy with ticlopidine and aspirin. A simplified approach to intracoronary stent management. Eur Heart J 1996; 17: 1373-1380.
5. Danchin N, Lablanche JM, Grollier G et al. Intracoronary stenting in patients with unstable angina. Results from the French TASTE study. Eur Heart J 1997; 18 (suppl.): 389 (abstract P 2220).
6. Kastrati A, Schulen H, Hausleiter J et al. Restenosis after coronary stent placement and randomization to a 4-week combined antiplatelet or anticoagulant therapy. Circulation 1997; 96: 462-467.
7. Coller BS, Anderson K, Weisman HF. New antiplatelet agents: platelet GP IIb-IIIa antagonists. Thromb Haemostasis 1995: 74: 302-308.
8. Baron JH, De Bono D, Gershlick AH. c7E3 Fab inhibits adhesion of smooth cells to vitronectin and osteopontin: a possible way of inhibiting in stent restenosis. Am J Cardiol 1997; 80 (7A): 20S (abstract).
9. Reverter JC, Beguin S, Kessels H, Kumar R, Hemker HC, Coller BS. Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody. J. Clin Invest 1996; 98(3): 863-874.
10. The EPIC Investigators. Use of monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high risk coronary angioplasty. N Engl J Med 1994; 330: 956-961.
11. The EPIC Investigators. Randomized trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at 6 months. Lancet 1994; 343: 881-886.
12. The EPIC Investigators. Long term protection from myocardial ischemic events in a randomized trial of brief integrin β3 blockade with percutaneous coronary intervention. JAMA 1997; 278 (6): 479-484.
13. The EPILOG Investigators. Platelet glycoprotein IIb/IIIa Receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997; 336 (24): 1689-1696.
14. The CAPTURE Investigators. Refractory unstable angina: reduction of events by treatment with abciximab prior to coronary intervention. Lancet 1997; 349: 1429-1435.
15. Van den Brand M, De Scheerder I, Heyndrickx G et al. Assessment of angioplasty outcome in patients with refractory unstable angina pretrcated with ReoPro. Eur Heart J 1997; 18 (Suppl A): 621 (abstract P3604).
16. Kereiakes D, Lincoff AM, Miller DP et al. Abciximab reduces risk of unplanned coronary stent deployment: EPILOG trials results. Circulation 1997; 96 (8) (Suppl I): I-163 (abstract 906).
17. Brami M, Côté G, Bonan R. Aspects cliniques, expérimentaux et physiopathologiques de la resténose après angioplastie coronaire. Arch Mal Cœur 1997; 90: 385-391.
18. Serruys PW, De Jaegere P, Kiemeneij F et al. A comparison of balloon-expandable stent implantation with balloon angioplasty in patients with coronary artery disease. N Engl J Med 1994; 331 (8): 489-495.
19. Fishman DL, Leon M, Baim DS et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. N Engl J Med 1994; 331: 496-501.
20. Sutton J, Ellis S, Roubin G et al. Major clinical events after coronary stenting. The multicenter registry of acute and elective Gianturco-Roubin stent placement. Circulation 1994; 89: 1126-1137.
21. Schömig A, Neumann FJ, Kastrati A et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary artery stents. N Engl J Med 1996; 334: 1084-1089.
22. Neumann FJ, Gawaz M, Ott I, Mossnmer G, Schomig A. Prospective evaluation of hemostatic predictors of subacute stent thrombosis after coronary Palmaz-Schatz stenting. J Am Coll Cardiol 1996; 27: 15-21.
23. Gawaz M, Neumann FJ, Ott I, May A, Schomig A. Platelet activation and coronary stent implantation. Effect of antithrombotic therapy. Circulation 1996; 94: 279-285.
24. Markowitz JH, Roubin GS, Parks JM and Bittner U. Platelet activation and restenosis after coronary stenting: flow cytometric detection of wound-induced platelet activation. Coronary Artery Disease 1996; 7: 657-665.
25. Kolarov P, Tschoepe D, Nieuwenhuis HK et al. PTCA: periprocedural platelet activation - Part II of the Dusseldorf PTCA platelet study (DFPS). Eur Heart J 1996; 17: 1216-1222.
26. Gregorini L, Marco J, Fajadet J et al. Ticlopidine and aspirin pretreatment reduces coagulation and platelet activation during coronary dilatation procedures. J Am Coll Cardiol 1997; 29: 13-20.
27. Zidar JP, Kruse K, Kereiakes D et al. Integrelin for emergency coronary artery stenting. JACC 1996; 27 (2-suppl. A): 138 A (abstract).
28. The RESTORE Investigators. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation 1997; 96: 1145-1153.
29. Topol EJ, Leya F, Pinkerton C et al. A comparison of directional atherectomy with coronary angioplasty in patients with coronary artery disease. N Engl J Med 1993; 329: 221-227.
30. Holmes D, Topol EJ, Califf M et al. A multicenter, randomized trial of coronary angioplasty versus directional atherectomy for patients with saphenous vein bypass graft lesions. Circulation 1995; 91: 1966-1974.
31. Ellis SG, Serruys PW, Popma JJ et al. Can abciximab prevent neointimital proliferation in Palmatz-Schatz stents? The final ERASER results. Circulation 1997; 96 (8) (Suppl I): I-87 (abstract 476).
32. Baron JH, Aggrawal R, De Bono D, Gershlick AH. Polymer coated stent wires eluting c7E3 Fab inhibit platelet aggregation in vitro. Am J Cardiol 1997; 80 (7A): 9S (abstract).